在肺癌患者中对SOCS,STAT和PIAS基因的基因表达分析
Solmaz Abolghasemi1, Maryam Bikhof Torbati2, Parviz Pakzad3
1College of Biology Sciences, Islamic Azad University, North Tehran Branch, Tehran, Iran.
Pathology, research and practice
|August 16, 2023
概括
这项研究研究了非小细胞肺癌 (NSCLC) 中的STAT,SOCS和PIAS基因表达. 在肺瘤,特别是腺癌中发现了更高的STAT3表达,这表明它是潜在的治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因表达分析 基因表达分析
背景情况:
- 肺癌,特别是非小细胞肺癌 (NSCLC),在全球范围内患病率和死亡率很高.
- STAT,SOCS和PIAS基因家族在癌症关键的细胞过程中发挥作用,包括血管生成,增殖和分化.
研究的目的:
- 检查NSCLC组织中STAT,SOCS和PIAS家族基因的表达水平.
- 研究这些基因表达与NSCLC,特别是腺癌的临床病理特征之间的相关性.
主要方法:
- 使用定量逆转录聚合酶链反应 (QRT-PCR) 来评估基因表达水平.
- 将瘤组织与相邻的正常组织之间的基因表达进行了比较.
- 表达水平与组织学等级和亚型 (腺癌) 相比进行了分析.
主要成果:
- 与正常组织相比,NSCLC瘤组织中的STAT3基因表达显著更高.
- 增加的STAT3表达与腺癌的较高组织学级相关.
- SOCS1和SOCS2基因表达显示了瘤的非显著减少,在腺癌亚型中观察到显著减少.
- 在瘤和正常组织之间,PIAS1表达没有显著差异.
结论:
- 在NSCLC中,特别是腺癌中,STAT3被上调,并可能作为潜在的生物标志物或治疗点.
- 在腺癌中,SOCS1和SOCS2的下调值值得进一步研究.
- 研究的基因 (STAT,SOCS,PIAS家族) 是未来NSCLC研究和治疗策略的潜在目标.
更多相关视频
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
6.8K
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
9.0K
相关概念视频
01:20The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
01:22PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K